In this randomized controlled study, individuals taking dolutegravir+darunavir/ritonavir had greater increases in systolic and diastolic blood pressure than those taking 2 nucleoside reverse-transcriptase inhibitors+darunavir/ritonavir at week-48. The difference remained significant after controlling for confounding factors, including weight gain.
No takes yet. Share an insight, caveat, or question.
Nyein et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: